Lisa Kurland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lisa Kurland has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Lars Lind
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
6 shared publications- Thomas Kahan
Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
6 shared publications - Fredrik H. Nystrom
Department of Health, Medicine and Caring Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden
5 shared publications Håkan Melhus
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
5 shared publications- Ann-Christine Syvänen
Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
4 shared publications Julia Karlsson
Department of Medical Sciences (LK, UL, JK, HM, A-CS), Uppsala University Hospital, Uppsala, Sweden
4 shared publications
Latest Publications
- Open Access
- 1 July 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (7) , 836-839
The Relationship Between the Plasma Concentration of Irbesartan and the Antihypertensive Response Is Disclosed by an Angiotensin II Type 1 Receptor Polymorphism: Results From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial
Background. The aim of this study was to investigate the effect of the plasma concentration of irbesartan, a specific angiotensin II type 1 receptor (A
- 1 July 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (7) , 836-839
Open AccessThe Relationship Between the Plasma Concentration of Irbesartan and the Antihypertensive Response Is Disclosed by an Angiotensin II Type 1 Receptor Polymorphism: Results From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial
Background. The aim of this study was to investigate the effect of the plasma concentration of irbesartan, a specific angiotensin II type 1 receptor (A
- 1 August 2005
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 26 (9) , 443-447
Using genotyping to predict responses to anti-hypertensive treatment
- 1 August 2005
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 26 (9) , 443-447
Using genotyping to predict responses to anti-hypertensive treatment
- 1 January 2005
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 5 (2) , 133-142
Hypertension and SNP Genotyping in Antihypertensive Treatment
- 1 January 2005
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 5 (2) , 133-142
Hypertension and SNP Genotyping in Antihypertensive Treatment
- Open Access
- 28 September 2004
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 4 (1) , 16
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment
Background: Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment. Methods: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the β1-adrenergic receptor blocker atenolol for twelve weeks. Results: The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele. Conclusions: Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.
- 28 September 2004
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 4 (1) , 16
Open AccessSingle nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment
Background: Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment. Methods: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the β1-adrenergic receptor blocker atenolol for twelve weeks. Results: The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele. Conclusions: Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.
- 1 January 2004
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 17 (1) , 8-13
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
The renin-angiotensin-aldosterone system (RAAS) is important for the development of hypertension, and several antihypertensive drugs target this system. Our aim was to determine whether specific single nucleotide polymorphisms (SNPs) in RAAS genes were related to the blood pressure (BP) lowering effect of antihypertensive treatment. Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy. A microarray-based minisequencing system was used to genotype 30 SNPs in seven genes in the RAAS. These polymorphisms were related to the antihypertensive response after 12 weeks treatment. The BP reductions were similar in the atenolol and the irbesartan groups. Presence of the angiotensinogen (AGT) -6A allele or the AGT 235T allele were both associated with the most pronounced systolic BP response to atenolol treatment (P =.001 when -6 AA+AG was compared with GG and P =.008 for presence of the 235T variant compared with 235 MM). We found that SNPs in the angiotensinogen gene were associated with the BP lowering response to atenolol. This study is limited by a relatively small sample size, and the results should therefore be viewed as preliminary. Despite this limitation, these results illustrate the potential of using SNP genotyping as a pharmacogenetic tool in antihypertensive treatment.
- 1 January 2004
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 17 (1) , 8-13
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
The renin-angiotensin-aldosterone system (RAAS) is important for the development of hypertension, and several antihypertensive drugs target this system. Our aim was to determine whether specific single nucleotide polymorphisms (SNPs) in RAAS genes were related to the blood pressure (BP) lowering effect of antihypertensive treatment. Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy. A microarray-based minisequencing system was used to genotype 30 SNPs in seven genes in the RAAS. These polymorphisms were related to the antihypertensive response after 12 weeks treatment. The BP reductions were similar in the atenolol and the irbesartan groups. Presence of the angiotensinogen (AGT) -6A allele or the AGT 235T allele were both associated with the most pronounced systolic BP response to atenolol treatment (P =.001 when -6 AA+AG was compared with GG and P =.008 for presence of the 235T variant compared with 235 MM). We found that SNPs in the angiotensinogen gene were associated with the BP lowering response to atenolol. This study is limited by a relatively small sample size, and the results should therefore be viewed as preliminary. Despite this limitation, these results illustrate the potential of using SNP genotyping as a pharmacogenetic tool in antihypertensive treatment.
- Open Access
- 18 September 2003
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 3 (1) , 11
Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy
- 18 September 2003
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 3 (1) , 11
Open AccessAdipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy
- 1 August 2003
- Vol. 94 (4) , 251-8
The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.
Coronary heart disease is the leading cause of death in the Western world. Approximately half of all the people who have their 1st heart attack and 2/3 of those with their first stroke have high blood pressure levels. Hypertension affects approximately 25% of the adult population. By treating hypertension and risk factors that contribute to cardiovascular disease both mortality and morbidity can be reduced. Many drugs have proven to be effective in treating hypertension, although the individual patient's response to antihypertensive treatment varies over a wide range and cannot be predicted with methods used today. Between 30-60% of the blood pressure variation is determined by genetic factors. Also the variation in drug response is in part heritable, which defines pharmacogenetics. This review gives a general background to pharmacogenetics and its potential usage. In addition, results from recent pharmacogenetics studies on the antihypertensive effect of the angiotensin II type 1 receptor antagonist irbesartan are presented.
- 1 August 2003
- Vol. 94 (4) , 251-8
The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.
Coronary heart disease is the leading cause of death in the Western world. Approximately half of all the people who have their 1st heart attack and 2/3 of those with their first stroke have high blood pressure levels. Hypertension affects approximately 25% of the adult population. By treating hypertension and risk factors that contribute to cardiovascular disease both mortality and morbidity can be reduced. Many drugs have proven to be effective in treating hypertension, although the individual patient's response to antihypertensive treatment varies over a wide range and cannot be predicted with methods used today. Between 30-60% of the blood pressure variation is determined by genetic factors. Also the variation in drug response is in part heritable, which defines pharmacogenetics. This review gives a general background to pharmacogenetics and its potential usage. In addition, results from recent pharmacogenetics studies on the antihypertensive effect of the angiotensin II type 1 receptor antagonist irbesartan are presented.
- 20 February 2003
- Vol. 100 (8) , 600-3
[Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy].
The variations in response to pharmacotherapy can in part be explained by genetic factors. Pharmacogenetics, a term coined in the 1950's, describes these relationships. Great technological advances in molecular biology and computational sciences, crowned by the sequencing of the human genome, have brought forth the current interest in pharmacogenetics. Continued technological developments may lead to the understanding of the molecular mechanisms behind complex diseases like cardiovascular disease, and holds the promise of individualized pharmacotherapy. The article gives a background to the field, with emphasis on antihypertensive therapy, and prospects for the future.
- 20 February 2003
- Vol. 100 (8) , 600-3
[Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy].
The variations in response to pharmacotherapy can in part be explained by genetic factors. Pharmacogenetics, a term coined in the 1950's, describes these relationships. Great technological advances in molecular biology and computational sciences, crowned by the sequencing of the human genome, have brought forth the current interest in pharmacogenetics. Continued technological developments may lead to the understanding of the molecular mechanisms behind complex diseases like cardiovascular disease, and holds the promise of individualized pharmacotherapy. The article gives a background to the field, with emphasis on antihypertensive therapy, and prospects for the future.
- 1 January 2003
- Published by Rockefeller University Press
- Vol. 13 (1) , 7-17
A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.
We aimed to develop a microarray genotyping system for multiplex analysis of a panel of single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in blood pressure regulation, and to apply this system in a pilot study demonstrating its feasibility in the pharmacogenetics of hypertension. A panel of 74 SNPs in 25 genes involved in blood pressure regulation was selected from the SNP databases, and genotyped in DNA samples of 97 hypertensive patients. The patients had been randomized to double-blind treatment with either the angiotensin II type 1 receptor blocker irbesartan or the beta 1-adrenergic receptor blocker atenolol. Genotyping was performed using a microarray based DNA polymerase assisted 'minisequencing' single nucleotide primer extension assay with fluorescence detection. The observed genotypes were related to the blood pressure reduction using stepwise multiple regression analysis. The allele frequencies of the selected SNPs were determined in the Swedish population. The established microarray-based genotyping system was validated and allowed unequivocal multiplex genotyping of the panel of 74 SNPs in every patient. Almost 7200 SNP genotypes were generated in the study. Profiles of four or five SNP-genotypes that may be useful as predictors of blood pressure reduction after antihypertensive treatment were identified. Our results highlight the potential of microarray-based technology for SNP genotyping in pharmacogenetics.
- 1 January 2003
- Published by Rockefeller University Press
- Vol. 13 (1) , 7-17
A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.
We aimed to develop a microarray genotyping system for multiplex analysis of a panel of single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in blood pressure regulation, and to apply this system in a pilot study demonstrating its feasibility in the pharmacogenetics of hypertension. A panel of 74 SNPs in 25 genes involved in blood pressure regulation was selected from the SNP databases, and genotyped in DNA samples of 97 hypertensive patients. The patients had been randomized to double-blind treatment with either the angiotensin II type 1 receptor blocker irbesartan or the beta 1-adrenergic receptor blocker atenolol. Genotyping was performed using a microarray based DNA polymerase assisted 'minisequencing' single nucleotide primer extension assay with fluorescence detection. The observed genotypes were related to the blood pressure reduction using stepwise multiple regression analysis. The allele frequencies of the selected SNPs were determined in the Swedish population. The established microarray-based genotyping system was validated and allowed unequivocal multiplex genotyping of the panel of 74 SNPs in every patient. Almost 7200 SNP genotypes were generated in the study. Profiles of four or five SNP-genotypes that may be useful as predictors of blood pressure reduction after antihypertensive treatment were identified. Our results highlight the potential of microarray-based technology for SNP genotyping in pharmacogenetics.
- 1 May 2002
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 15 (5) , 389-393
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial
Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 +/- 19 SD mm Hg, n = 17) than both the TC (-14 +/- 18 mm Hg, n= 18) and CC (0 +/- 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.
- 1 May 2002
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 15 (5) , 389-393
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial
Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 +/- 19 SD mm Hg, n = 17) than both the TC (-14 +/- 18 mm Hg, n= 18) and CC (0 +/- 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.